Skip to main content

Hypovolemic Shock

0
Pipeline Programs
3
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Pharmazz
PharmazzIndia - Greater Noida
4 programs
Normal SalinePHASE_21 trial
Normal SalinePHASE_31 trial
Normal saline + Standard TreatmentPHASE_31 trial
CenthaquinePHASE_41 trial
Active Trials
NCT04056065Completed50Est. Oct 2018
NCT05251181Not Yet Recruiting430Est. Oct 2027
NCT04045327Completed105Est. Sep 2019
+1 more trials
Defence Therapeutics
Defence TherapeuticsBC - Vancouver
1 program
Reinfusion - Sternal IO needleN/A1 trial
Active Trials
NCT02924792Completed30Est. Dec 2017
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
non-pneumatic anti-shock garmentN/A1 trial
Active Trials
NCT00488462Completed887Est. May 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
PharmazzCenthaquine
PharmazzNormal Saline
PharmazzNormal saline + Standard Treatment
PharmazzNormal Saline
Defence TherapeuticsReinfusion - Sternal IO needle
Human BioSciencesnon-pneumatic anti-shock garment

Clinical Trials (6)

Total enrollment: 1,902 patients across 6 trials

NCT05956418PharmazzCenthaquine

A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients

Start: Aug 2021Est. completion: Aug 2026400 patients
Phase 4Recruiting
NCT05251181PharmazzNormal Saline

A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent

Start: Feb 2026Est. completion: Oct 2027430 patients
Phase 3Not Yet Recruiting
NCT04045327PharmazzNormal saline + Standard Treatment

Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock

Start: Jan 2019Est. completion: Sep 2019105 patients
Phase 3Completed
NCT04056065PharmazzNormal Saline

PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock

Start: May 2017Est. completion: Oct 201850 patients
Phase 2Completed
NCT02924792Defence TherapeuticsReinfusion - Sternal IO needle

Sternal Intraosseous Transfusion of Autologous Whole Blood: A Comparison of Flow Rates and Degree of Hemolysis

Start: Nov 2016Est. completion: Dec 201730 patients
N/ACompleted
NCT00488462Human BioSciencesnon-pneumatic anti-shock garment

Non-Pneumatic Anti-Shock Garment for Obstetrical Hemorrhage: Zambia and Zimbabwe

Start: Oct 2007Est. completion: May 2012887 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,902 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.